

PharmaMar signs a new agreement with STA to commercialize Yondelis® in Australia, New Zealand and South East Asia

- **PharmaMar shall receive an upfront payment and is eligible for additional remunerations, including regulatory milestone payments.**
- **While Yondelis® (trabectedin) is already commercially available in several Asian countries, STAsia will now seek regulatory approval from the Therapeutic Goods Administration (TGA) in Australia.**

Madrid, October 14th, 2019. – PharmaMar (MSE:PHM) has announced today a licensing agreement with Specialised Therapeutics Asia, Pte. Ltd. (STA) to commercialize the marine-derived anticancer drug Yondelis® (trabectedin) in Australia, New Zealand and South East Asia.

Under the terms of the agreement, PharmaMar shall receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory milestone payments. PharmaMar will retain exclusive production rights of the product and will sell the product to STA for its clinical and commercial use.

This new agreement follows PharmaMar's announcement on 26 August, regarding the agreement entered with Janssen Products LP (Janssen), by which PharmaMar recovered the commercialization rights of the product in more than 40 countries, formerly licensed to Janssen, where trabectedin has already been approved.

Through its partner STA, PharmaMar expects to see this compound access the markets of Australia and New Zealand, where trabectedin has not been available to date.

STA will seek formal regulatory approval to market Yondelis® (trabectedin) in Australia from the Therapeutic Goods Administration (TGA) and subsequent reimbursement through the Pharmaceutical Benefits Scheme (PBS).

In the interim, a Special Access Program in Australia will be opened on November 1st to ensure trabectedin is available at the earliest opportunity to eligible patients with Soft Tissue Sarcoma.



Trabectedin is currently provided to patients in Singapore, Malaysia and Brunei for the treatment of Soft Tissue Sarcoma and Recurrent Ovarian Cancer.

Former product licensee Janssen will continue to commercialize the product in those territories until its marketing authorizations are formally transferred to STA.

José María Fernández, PhD, President of PharmaMar, commented: *"This new license arrangement is the third we have struck with STA, and is a strong endorsement of their capabilities in these key marketing regions of Australia, New Zealand and South-East Asia."* He added, *"Patients and the medical community will now be provided with the opportunity to readily access Yondelis®, which is already recognized as a global standard of care in Soft Tissue Sarcoma. We look forward to seeing sarcoma patients benefit with improved outcomes."*

Announcing the new deal, STA Chief Executive Officer, **Mr. Carlo Montagner** said some Australian patients and their doctors had previously sought to access the compound from international sources, at great difficulty and expense. *"Trabectedin is regarded as a global standard of care to treat soft tissue sarcoma. We are delighted to provide this important therapy to patients in Australia, New Zealand and in South-East Asia,"* he said. *"We will be immediately seeking approval from the Therapeutic Goods Administration (TGA) and in the interim, will ensure trabectedin is available to appropriate patients via a Special Access Program."*

Associate Professor Jayesh Desai, Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, and Deputy-Chair of the Australia New Zealand Sarcoma Association (ANZSA), commented on the importance of the availability of trabectedin in Australia for sarcoma patients. *"Sarcoma is a relatively rare cancer and treatment options are limited for Australian patients with advanced disease,"* Associate Professor Desai added *"Trabectedin has been shown to provide a 45% reduction in the risk of disease progression or death versus dacarbazine in patients who have failed prior therapy¹, and has been a global standard of care. We welcome the news that Australian patients will soon be provided access to this therapy that is already providing benefit to sarcoma patients around the world."*

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

¹ Demetri G. et al. J Clin Oncol. 2016; 34(8): 786-793

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Specialised Therapeutics Asia

Headquartered in Singapore, Specialised Therapeutics Asia Pte Ltd (STA) is an international biopharmaceutical company established to commercialise new therapies and technologies to patients throughout South East Asia, as well as in Australia and New Zealand. STA and its regional affiliates collaborate with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life-changing healthcare solutions to patients affected by a range of diseases. Its mission is to provide therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, neurology, ophthalmology and supportive care. Additional information can be found at www.stbiopharma.com

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com